Core Insights - SeoulCeuticals positions itself as a unique US-based skincare brand sourcing authentic Korean ingredients, addressing the rising consumer demand for traditional Korean heritage in beauty products [1][2]. Industry Overview - The modernization of hanbang, traditional Korean herbal medicine, is identified as the defining trend in K-beauty for 2026, merging traditional practices with modern scientific validation [2]. - The global K-beauty market reached $11.1 billion in 2025, with North America accounting for $3.1 billion, indicating significant market potential for brands like SeoulCeuticals [3]. Company Profile - Founded in 2017, SeoulCeuticals has nearly a decade of experience in sourcing and formulating products with Korean heritage ingredients, including Panax Ginseng Extract, Rice Bran, Snail Mucin, and PDRN [2][4]. - The brand emphasizes quality control by manufacturing in US facilities, ensuring faster delivery to North American customers [4]. Product Efficacy - Clinical research highlights the skin benefits of key heritage ingredients: - Panax Ginseng's ginsenosides inhibit collagen degradation - Fermented Rice Bran enhances skin barrier and provides gentle exfoliation - Snail Mucin supports collagen synthesis and fibroblast proliferation [5][12]. - The synergy of these ingredients reflects the hanbang philosophy, where each component enhances the others [6]. Product Offerings - SeoulCeuticals' Snail Mucin + Niacinamide Serum features a high concentration of Snail Mucin (97.5%) combined with other beneficial ingredients, showcasing the brand's approach to multi-active formulations [7]. - The Day Glow Serum incorporates multiple Korean-sourced actives, moving away from reliance on a single hero ingredient [7]. Expert Commentary - The brand's philosophy emphasizes prevention over treatment, with a focus on the synergistic effects of its heritage ingredients [8]. Brand Commitment - SeoulCeuticals aims to provide quality, natural beauty solutions while honoring Korean beauty traditions, offering vegan and cruelty-free formulations suitable for all skin types [9].

Financial Performance - Revenues from continuing operations increased by $0.2 million, or 8%, to $2.1 million in Q1 2024 compared to Q1 2023[94] - Gross profit from continuing operations rose by $0.2 million in Q1 2024 compared to Q1 2023, with cost of goods sold remaining at $1.7 million for both periods[94] - Loss from continuing operations was $1.4 million in Q1 2024, compared to a loss of $1.2 million in Q1 2023, with net loss per share decreasing to $0.15 from $0.18[98] Expenses - Selling, general and administrative expenses increased to $1.7 million in Q1 2024 from $1.4 million in Q1 2023, primarily due to higher legal costs[96] Cash Flow and Financial Position - The company had an accumulated deficit of $335.1 million and cash and cash equivalents of $0.4 million as of March 31, 2024[99] - Operating cash used in Q1 2024 was $1.4 million, compared to $0.5 million of cash provided in Q1 2023[99] Financing Activities - Funicular purchased $0.4 million of common stock and lent the company $4.1 million on December 1, 2023, with warrants for up to 5.0 million shares[101][102] - The company sold Golden Ridge for $2.2 million on January 25, 2024, streamlining its business and eliminating unprofitable operations[103] - The company is exploring additional financing options but faces uncertainty regarding the availability and terms of such financing[104] Internal Controls - Management identified material weaknesses in internal controls over financial reporting, leading to an overstatement in inventory[111]

Financial Performance - Revenues from continuing operations were $22.6 million in 2023, a decrease of $4.0 million, or 15.0%, compared to $26.6 million in 2022[100] - Loss from continuing operations in 2023 was $8.6 million, or $1.22 per share, compared to a loss of $6.7 million, or $1.21 per share in 2022[102] - Net loss in 2023 was $17.6 million, or $2.51 per share, compared to a net loss of $7.9 million, or $1.42 per share in 2022[103] - Selling general and administrative (SG&A) expenses increased by $0.5 million, or 9.3%, to $5.9 million in 2023[101] Cash Position - As of December 31, 2023, the company had an accumulated deficit of $333.3 million and cash and cash equivalents of $1.1 million[91] - The company used $2.2 million in operating cash during 2023, compared to $3.8 million in 2022[104] Financing Activities - On December 1, 2023, Funicular purchased $0.4 million of shares and lent the company $4.1 million[93] - The company believes additional cash can be secured through other debt or structured equity financing if necessary[96] Business Operations - The company sold Golden Ridge for $2.15 million on January 25, 2024, streamlining its business and eliminating unprofitable operations[95] - The company recorded a $1.5 million impairment charge in the fourth quarter related to the sale of Golden Ridge[102]

Financial Performance - Revenues for the third quarter of 2023 were $4.8 million, a decrease of $1.8 million or 26.8% from $6.6 million in the third quarter of 2022 [90]. - Revenues for the first nine months of 2023 were $17.0 million, a decrease of $2.2 million or 11.7% from $19.2 million in the same period of 2022 [95]. - Loss from continuing operations for the third quarter of 2023 was $1.8 million, or $0.26 per share, compared to $2.0 million, or $0.29 per share, in the third quarter of 2022 [94]. - Loss from continuing operations for the first nine months of 2023 was $5.1 million, or $0.77 per share, compared to $5.4 million, or $1.03 per share, in the same period of 2022 [99]. Gross Loss - The gross loss for the third quarter of 2023 decreased by $0.1 million or 15.5% compared to the third quarter of 2022, attributed to the rationalization of less profitable business [91]. - The gross loss for the first nine months of 2023 improved by 47.9% to $0.5 million from a gross loss of $1.0 million in the first nine months of 2022 [96]. Expenses - Selling, general and administrative (SG&A) expenses were $1.2 million in the third quarter of 2023, a decrease of $0.2 million or 12.7% from $1.4 million in the third quarter of 2022 [92]. - SG&A expenses increased by $0.3 million or 8.3% to $4.3 million in the first nine months of 2023 compared to $4.0 million in the same period of 2022 [97]. Cash Position - As of September 30, 2023, the company had $0.5 million in cash and equivalents, a decline of $0.6 million from December 31, 2022 [100]. - The company believes the recent financing will be adequate to fund its planned operations over the next twelve months [103].

Financial Performance - Revenues for the second quarter of 2023 were $6.3 million, a decrease of $0.3 million, or 4.7%, from $6.6 million in the second quarter of 2022[98] - Revenues for the first half of 2023 were $12.1 million, a decrease of $0.5 million, or 3.7%, from $12.6 million in the first half of 2022[103] - Loss from continuing operations for the second quarter of 2023 was $1.8 million, or $0.27 per share, compared to $2.2 million, or $0.41 per share, in the second quarter of 2022[102] - Loss from continuing operations in the first half of 2023 was $3.4 million, or $0.50 per share, compared to $3.9 million, or $0.74 per share, in the first half of 2022[108] Gross Profit and Loss - Gross profit for the second quarter of 2023 was $24 thousand, compared to a gross loss of $0.4 million in the second quarter of 2022[99] - Gross loss for the first half of 2023 improved to $34 thousand from a gross loss of $0.4 million in the first half of 2022[104] Expenses - Selling, general and administrative (SG&A) expenses increased to $1.6 million in the second quarter of 2023, up $0.4 million from $1.2 million in the second quarter of 2022[100] - SG&A expenses for the first half of 2023 were $3.1 million, an increase of $0.5 million compared to $2.6 million in the first half of 2022[105] Cash Position and Future Outlook - Cash and equivalents as of June 30, 2023, were $0.3 million, a decline of $0.6 million from December 31, 2022[109] - The company believes there is no substantial doubt about its ability to continue as a going concern within one year, citing expected improvements in profitability and access to additional capital[111]

Financial Performance - Revenues for the three months ended March 31, 2023, were $9,269,000, a decrease of 12.2% compared to $10,559,000 for the same period in 2022[11] - Gross profit for Q1 2023 was a loss of $282,000, compared to a profit of $502,000 in Q1 2022, indicating a significant decline in profitability[11] - Operating loss increased to $2,013,000 in Q1 2023 from $1,190,000 in Q1 2022, reflecting ongoing challenges in cost management[11] - Net loss for the three months ended March 31, 2023, was $2,028,000, compared to a net loss of $1,516,000 in the same period last year, representing a 33.7% increase in losses[11] - Cash flow from operating activities was a net outflow of $62,000 for Q1 2023, a decline from a net inflow of $190,000 in Q1 2022[15] Assets and Liabilities - Cash and cash equivalents decreased to $3,412,000 as of March 31, 2023, down from $3,941,000 at the end of 2022[13] - Total current assets decreased to $10,300,000 as of March 31, 2023, compared to $11,068,000 at December 31, 2022[13] - Total liabilities increased to $15,346,000 as of March 31, 2023, from $14,524,000 at the end of 2022, indicating a rise in financial obligations[13] - Long-term debt as of March 31, 2023, totaled $2,344,000, slightly up from $2,292,000 as of December 31, 2022[52] - The company had an average borrowing of $2,771,000 during the three months ended March 31, 2023, with interest paid as a percentage of average outstanding borrowings at 2.2%[48] Equity and Stock - The company reported a basic loss per share of $0.31 for Q1 2023, compared to a loss of $0.29 per share in Q1 2022[11] - The weighted average number of common shares outstanding increased to 6,337,031 in Q1 2023 from 5,166,491 in Q1 2022, reflecting a 22.6% increase in shares[68] - The company had 277,479 restricted stock units (RSUs) nonvested as of March 31, 2023, down from 366,818 RSUs at the end of 2022, indicating a reduction of 24.3%[61] - As of March 31, 2023, the company had 320,813 vested RSUs, which is an increase from 224,725 vested RSUs at the end of 2022, representing a 42.6% increase[61] Inventory and Receivables - Total inventories increased to $2.562 million as of March 31, 2023, from $2.378 million as of December 31, 2022, reflecting a growth of approximately 7.7%[35] - Accounts receivable from significant customers accounted for 17% and 10% of revenue for the three months ended March 31, 2023, compared to 11% and 5% for the same period in 2022[32] Other Income and Expenses - The company recognized share-based compensation expense of $300,000 for the three months ended March 31, 2023, compared to $241,000 for the same period in 2022, which is a 24.5% increase[60] - The company received $0.3 million in restitution payments from a former employee, contributing to other income in Q1 2023[77] - Other income for the three months ended March 31, 2023, includes a $0.3 million gain from collecting the restitution payment[77] Business Operations - The company continues to focus on developing specialty ingredients derived from rice bran, with ongoing production at multiple facilities across the U.S.[21] - The company continues to focus on developing and marketing products derived from rice bran, addressing consumer demand for natural and non-GMO products[21] Legal and Compliance - The company is involved in litigation related to employment, patent claims, and alleged non-compliance with contract provisions, but management believes these will not materially affect financial position or results[76]

Company Overview - The company is a market leader in North America for converting raw rice bran into stabilized rice bran (SRB) and high-value SRB derivative products[12]. - The company operates two specialty mills, including a rice mill in Arkansas and a grain mill in Minnesota, enhancing its production capabilities[16][36]. - The company focuses on developing, producing, and marketing specialty ingredients derived from traditional and ancient small grains, emphasizing natural, non-GMO, and organic products[144]. - The company produces stabilized rice bran (SRB) and high value-added derivative products, including RiBalance, RiSolubles, RiFiber, and ProRyza, which cater to health-conscious consumers[145]. - The company operates four production facilities, including two in California and two in the Louisiana and Arkansas delta region, with additional specialty milling facilities in Montana and Minnesota[147]. - The company has one reporting unit and one operating segment, which is specialty ingredients, reflecting the integrated nature of its products and production facilities[148]. Financial Performance - Revenues for 2022 were $41.6 million, an increase of $10.5 million or 33.7% compared to $31.1 million in 2021, driven by strong growth in MGI and Golden Ridge milling operations[105]. - Total revenues for 2022 were $41.617 million, a 33.6% increase from $31.131 million in 2021[133]. - The company reported a net loss of $7.858 million in 2022, compared to a net loss of $8.949 million in 2021, indicating a reduction in losses[133]. - Operating loss was $7.2 million in 2022, an improvement from an operating loss of $10.6 million in 2021, due to reduced gross losses and improved SG&A[109]. - Cash and equivalents as of December 31, 2022, were $3.9 million, a decline of $1.9 million from $5.8 million on December 31, 2021[111]. - Cash used in operating activities in 2022 was $3.9 million, compared to $4.2 million in 2021, primarily driven by increased net losses[111]. - The company recognized a gain of $0.1 million in 2022 on the involuntary conversion of assets related to hurricane damage insurance claims[108]. - The company expects improved operating cash flows in 2023 due to the transition of sourcing and selling activities for its Arkansas mill and capital investments in its Minnesota mill[140]. - The transition of the Arkansas mill to a service provider resulted in its first positive quarterly contribution to operating cash flows in Q4 2022[140]. - The Minnesota mill saw a significant increase in sales and profit contribution in Q4 2022 due to additional capacity coming online[140]. Customer Concentration and Market Demand - In 2022, three customers accounted for 29.2% of the company's revenues, indicating a need for diversification of the customer base[39]. - The company anticipates further adoption of its ingredients by food companies due to increasing consumer demand for minimally processed, non-GMO, gluten-free ingredients[38]. - The company relies on a limited number of customers, with significant credit risk associated with outstanding accounts receivable, which could adversely affect operations[68]. - In 2022, three customers accounted for 29.2% of revenues, and the top ten customers represented 54.4% of revenues, highlighting a significant customer concentration risk[66]. Operational Challenges - The company has experienced increased competition, which negatively impacted financial results in 2022 and is expected to continue affecting performance[47]. - The company must increase marketing efforts to raise awareness of rice bran products, requiring substantial management and financial resources[70]. - The company’s production capacity is currently limited, and any dramatic increase in demand may require additional investment and time to scale operations[71]. - The company faces inflationary pressures that could increase operating expenses and affect its ability to service debt, potentially impacting profitability[60]. Compliance and Regulatory Issues - The company is committed to compliance with the FDA Food Safety Modernization Act (FSMA) and maintains SQF certification at all facilities[44]. - The company is subject to extensive laws and regulations, including those from the FDA and USDA, which could lead to significant compliance costs or loss of sales revenues if not adhered to[74]. Financial Liabilities and Risks - The company reported a net cash used in operating activities of $3.9 million in 2022 and $4.2 million in 2021, indicating ongoing financial challenges[54]. - As of December 31, 2022, the company has incurred an accumulated deficit exceeding $316 million, raising concerns about future profitability and financial viability[55]. - The company has a $7.0 million credit facility under a factoring agreement, which is secured by personal property assets, posing a risk if repayment is demanded[57]. - The company has $2.8 million remaining under an at-the-market offering program with an aggregate offering price of up to $6.0 million[113]. - Total liabilities increased to $14.524 million in 2022 from $12.818 million in 2021, reflecting a rise in current liabilities[131]. - The company has limited insurance coverage for many business risks, which could materially affect its financial condition in the event of significant uninsured claims[78]. Employee and Management Considerations - The company employs 94 individuals as of December 31, 2022, and focuses on creating a dynamic and inclusive work environment[49]. - The company is dependent on key employees, including top management, and may face challenges in attracting and retaining talent due to stock price volatility[81]. Stock and Equity Information - As of March 16, 2023, there are 6,384,334 shares of common stock outstanding, with an additional 2,349,083 shares issuable upon exercise of stock options and warrants, indicating a significant equity overhang[85]. - The company must maintain a minimum of $2.5 million in shareholders' equity and a minimum common stock bid price of $1.00 to comply with NASDAQ listing requirements[87]. - The company has never declared or paid any cash dividends on its common stock and plans to retain future earnings for business expansion[102]. Miscellaneous - The company is not currently involved in any material litigation, but may face legal proceedings in the ordinary course of business[97]. - The company’s stock price has experienced significant volatility, which may continue to affect investor perception and shareholder litigation risks[83].